Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SERPINH1 | P50454 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4865124 | 0.93 | ALDH1A1 (0.66) | ALDH1A1CYP2C19LMNATSHRSERPINH1 | |
| SCHEMBL5399073 | 0.88 | ALDH1A1 (0.60) | ALDH1A1CYP2C19LMNAKMT2AL3MBTL1 | |
| SCHEMBL5398966 | 0.88 | ALDH1A1 (0.60) | ALDH1A1CYP2C19LMNAMEN1KMT2A | |
| SCHEMBL5243446 | 0.88 | ALDH1A1 (0.59) | ALDH1A1CYP2C19LMNAKMT2ACYP3A4 | |
| SCHEMBL28732491 | 0.87 | ALDH1A1 (0.44) | ALDH1A1CYP2C19LMNASERPINH1MEN1 | |
| SCHEMBL5401473 | 0.87 | ALDH1A1 (0.62) | ALDH1A1CYP2C19LMNASERPINH1KMT2A | |
| SCHEMBL5244764 | 0.87 | ALDH1A1 (0.58) | ALDH1A1CYP2C19LMNAMEN1POLB | |
| SCHEMBL5414252 | 0.87 | ALDH1A1 (0.58) | ALDH1A1CYP2C19LMNAMEN1KMT2A | |
| SCHEMBL29434423 | 0.82 | ALDH1A1 (0.65) | ALDH1A1CYP2C19LMNAKMT2ACYP3A4 | |
| SCHEMBL16785484 | 0.82 | ALDH1A1 (0.65) | ALDH1A1CYP2C19LMNAKMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312335-B2 | Asymmetric Michael and Aldol additions using bifunctional cinchona-alkaloid-based catalysts | BRANDEIS UNIVERSITY (US) | 2007-12-25 | — | — | US | disclosed |
| US-20060014956-A1 | Asymmetric Michael and Aldol additions using bifunctional cinchona-alkaloid-based catalysts | BRANDEIS UNIVERSITY | 2006-01-19 | — | — | US | disclosed |
| EP-1512678-A1 | Process for preparing optically active nitro compounds and cyano compounds | Kanto Kagaku Kabushiki Kaisha (JP) | 2005-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014956-A1 | Asymmetric Michael and Aldol additions using bifunctional cinchona-alkaloid-based catalysts | ALDH3A1, NQO1, DERA | ALDH1A1 13/4885CYP2C19 631/4885LMNA 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.